Wesbanco Bank Inc. raised its position in PAREXEL International Corporation (NASDAQ:PRXL) by 12.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,068 shares of the medical research company’s stock after buying an additional 3,645 shares during the period. Wesbanco Bank Inc. owned approximately 0.07% of PAREXEL International Corporation worth $2,961,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Elkfork Partners LLC raised its stake in PAREXEL International Corporation by 7.1% in the first quarter. Elkfork Partners LLC now owns 3,060 shares of the medical research company’s stock worth $193,000 after buying an additional 204 shares during the last quarter. US Bancorp DE raised its stake in PAREXEL International Corporation by 3.5% in the first quarter. US Bancorp DE now owns 50,137 shares of the medical research company’s stock worth $3,164,000 after buying an additional 1,701 shares during the last quarter. Investment Management of Virginia LLC raised its stake in PAREXEL International Corporation by 2.7% in the first quarter. Investment Management of Virginia LLC now owns 14,985 shares of the medical research company’s stock worth $946,000 after buying an additional 395 shares during the last quarter. First Trust Advisors LP raised its stake in PAREXEL International Corporation by 216.7% in the first quarter. First Trust Advisors LP now owns 29,536 shares of the medical research company’s stock worth $1,864,000 after buying an additional 20,210 shares during the last quarter. Finally, LSV Asset Management raised its stake in PAREXEL International Corporation by 43.9% in the first quarter. LSV Asset Management now owns 380,751 shares of the medical research company’s stock worth $24,029,000 after buying an additional 116,200 shares during the last quarter. Hedge funds and other institutional investors own 87.49% of the company’s stock.

PAREXEL International Corporation (NASDAQ PRXL) opened at 87.88 on Thursday. The firm’s 50-day moving average is $87.51 and its 200 day moving average is $75.37. PAREXEL International Corporation has a 12-month low of $51.16 and a 12-month high of $87.89. The stock has a market capitalization of $4.46 billion, a P/E ratio of 42.66 and a beta of 0.79.

PAREXEL International Corporation (NASDAQ:PRXL) last released its earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.08. The firm had revenue of $557.20 million for the quarter, compared to analyst estimates of $537.59 million. PAREXEL International Corporation had a return on equity of 28.68% and a net margin of 5.12%. During the same period in the previous year, the company earned $0.94 earnings per share. Equities analysts expect that PAREXEL International Corporation will post $3.89 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/31/parexel-international-corporation-prxl-shares-bought-by-wesbanco-bank-inc.html.

A number of research firms have recently weighed in on PRXL. Zacks Investment Research upgraded shares of PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price objective on the stock in a research note on Thursday. BidaskClub lowered shares of PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Jefferies Group LLC restated a “hold” rating and set a $88.10 price target on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Barclays PLC lowered shares of PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a research report on Tuesday, June 20th. Finally, Raymond James Financial, Inc. upgraded shares of PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the company. PAREXEL International Corporation currently has a consensus rating of “Hold” and a consensus price target of $75.93.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.